Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

1
Player Avatar azurlo (< 20) Submitted: 2/10/2011 4:18:16 PM : Outperform Start Price: $2.35 PPHM Score: -73.41

Strong late stage pipeline

Featured Broker Partners


Advertisement